Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat

Eli Lilly reported third-quarter revenue of $24.4 billion, about $1.9 billion above consensus, and raised its full-year 2026 revenue guidance to $91 billion-$92 billion, nearly $10 billion above its initial outlook. Revenue grew 45.5% over the last 12 months to $86.5 billion, while the article notes roughly $900 million of favorable items in the quarter and about $2 billion of non-recurring items in the 2026 base. Bernstein reiterated Outperform with a $1,450 target, and several other firms raised targets; shares closed at $1,373.70, near their 52-week high, though the article cites valuation concerns.

Analysis

The key debate is whether demand converts into durable, profitable growth—not whether near-term revenue can beat. Revisions and elevated 2027 expectations raise the bar: if prescription growth is increasingly bought through lower net pricing, broader access, or heavier investment, revenue can remain strong while earnings conversion disappoints. The favorable items and non-recurring contributions flagged in the report also make headline guidance less clean as a run-rate measure; investors should track underlying sales, net price, and operating leverage separately.

Near term, the December 7 Innovation Day is a catalyst for expectations, not proof of incremental earnings. At a 52-week high after a large run, more analyst target increases may provide less support than a miss against the newly elevated bar. Over 1–3 months, verify prescription trends, supply availability, payer access and any 2027 outlook changes. Over 6–18 months, broader international access and pipeline progress could extend the franchise, while affordability pressure, competitive substitution from Novo Nordisk, or capacity constraints could limit monetization. The contrarian risk is that consensus extrapolates demand and successful launches while underweighting price/mix and execution; conversely, treating the business as merely a crowded momentum trade could understate the duration of category expansion.

Key Decisions for Investors

• Do not chase LLY at current highs solely on target-price revisions. For existing positions, retain core exposure but consider trimming or hedging event-sensitive excess ahead of Innovation Day; the article provides no options pricing to justify a specific structure.
• Add only on post-event weakness if underlying prescription growth, supply and access metrics remain intact and management supports the forward earnings path. Stage entries rather than making the December 7 event a binary bet.
• Set a thesis review trigger if guidance or analyst estimates roll over, or if sales growth increasingly depends on weaker net price/mix rather than volume. That would challenge earnings conversion even if reported revenue remains robust.
• Treat a long-LLY/short-Novo Nordisk pair as a watch item, not an immediate recommendation: first verify relative prescription/share trends, net pricing and valuation, which the article does not establish.